Oral MS Drug
Links shared publicly online about this topic
Oral MS Drug's Positive Result Buoys Biogen - WSJ.com
online.wsj.com — “The biotechnology company plans to seek regulatory approval early next year for its experimental pill, BG-12, after a clinical trial showed that patients had fewer MS relapses.” View full resource at online.wsj.com
Most Recently Shared on October 26, 2011 at 7:56 pm By:
Scott Strumello Patient Expert
http://t.co/Ld8D5lbR: Oral MS Drug's Positive Result Buoys Biogen http://t.co/4wUhsjan
Biogen Idec Reveals Clinical Data for (Really) Small Oral MS Drug BG-12 | The Haystack
cenblog.org — “Biogen Idec made a splash last week when its oral medication for multiple sclerosis (MS), BG-12, was found to reduce relapses in 44-53% of nearly 3,800 patients in two separate Phase 3 clinical trials (CONFIRM and DEFINE, respectively). Continued hopes for an orally available, non-injectable MS treatment have created a race between Biogen Idec and several [...]” View full resource at cenblog.org
Most Recently Shared on November 2, 2011 at 12:15 pm By:
Carmen Drahl Doctor, Science Enthusiast, and PhD
Biogen's MS drug candidate BG-12 bucks the trend for REALLY small molecules in drug development, says @SeeArrOh http://t.co/Q4RkDJPB $BIIB
Can Novartis Win Race to Launch First Oral Drug for MS? | BNET Pharma Blog | BNET
industry.bnet.com — “Novartis AG is jockeying with German drug maker Merck KgaA to deliver the first disease-modifying treatment for relapsing forms of multiple sclerosis” View full resource at industry.bnet.com
Most Recently Shared on December 3, 2009 at 10:28 pm By:
Jim Edwards Health Communicator
Can Novartis Win Race to Launch First Oral Drug for MS?: Novartis AG is jockeying with German drug maker Merck KgaA... http://bit.ly/6og2Df
Oral MS Drug Fampridine is Trifecta of Firsts for People with MS, Says National MS Society
prweb.com — “Pr: fda approves fampridine sr, now called ampyra, to improve walking for people with all types of multiple sclerosis. ampyra is the first symptom management drug developed specifically to treat ms, the first oral therapy approved for ms and the first new fda-approved therapy for ms since 2004. new york” View full resource at prweb.com
Most Recently Shared on January 23, 2010 at 2:40 am By:
Oral MS drug Fampridine is a trifecta of"firsts" for people with multiple sclerosis http://tinyurl.com/yhbszro
Cannabis Treatment Licensed For MS, UK
medicalnewstoday.com — “The first symptom relief drug specifically for people with multiple sclerosis (MS) has been licensed by the MHRA (Medicines and Healthcare products Regulatory Agency).'Sativex' is an oral” View full resource at medicalnewstoday.com
Most Recently Shared on June 22, 2010 at 1:11 pm By:
Cannabis Treatment Licensed For MS, UK http://mnt.to/3F9v #multiplesclerosis
New Oral Drugs Hailed for Treating MS
health.yahoo.net — “MONDAY, Jan. 31 (HealthDay News) -- For decades, research into treatments for multiple sclerosis has plodded forward, making slow but significant gains in improving the lives of people with the degenerative nerve disorder.” View full resource at health.yahoo.net
Most Recently Shared on January 31, 2011 at 3:20 pm By:
Jennifer Ann Grisso Nurse and Active Health Library
New Oral Drugs Hailed for Treating MS: MONDAY, Jan. 31 (HealthDay News) -- For decades, research into treatment... http://bit.ly/eXslsX
FDA Panel Votes to Approve Gilenia, First Oral MS Drug
webmd.com — “An FDA panel today overwhelmingly voted to approve Novartis's Gilenia, the first oral drug for multiple sclerosis. Gilenia has serious side effects; patients must be closely monitored.” View full resource at webmd.com
Most Recently Shared on June 10, 2010 at 10:47 pm By:
FDA Panel Votes to Approve Gilenia, First Oral MS Drug: An FDA panel today overwhelmingly voted to approve Novarti... http://bit.ly/bUdqX8
FDA Approves First Oral Drug To Reduce MS Relapses
medicalnewstoday.com — “The U.S. Food and Drug Administration has approved Gilenya capsules (fingolimod) to reduce relapses and delay disability progression in patients with relapsing forms of multiple sclerosis (MS).” View full resource at medicalnewstoday.com
Most Recently Shared on September 24, 2010 at 11:05 pm By:
MNT Drug Approvals Health News
FDA Approves First Oral Drug To Reduce MS Relapses http://mnt.to/3Khy #regulatory
FDA Approves First Oral Drug To Reduce MS Relapses
medicalnewstoday.com — “The U.S. Food and Drug Administration has approved Gilenya capsules (fingolimod) to reduce relapses and delay disability progression in patients with relapsing forms of multiple sclerosis (MS).” View full resource at medicalnewstoday.com
Most Recently Shared on September 23, 2010 at 2:37 pm By:
FDA Approves First Oral Drug To Reduce MS Relapses: The U.S. Food and Drug Administration has approved Gilenya cap... http://mnt.to/f/3Kdv
Oral BG-12 (Dimethyl Fumarate) Significantly Reduced Multiple Sclerosis (MS) Relapses and Disability Progression in Define Phase 3 Clinical Trial - Drugs.com MedNews
drugs.com — “240 mg of BG-12 Administered Either Twice or Three Times Oct 21, 2011 - Today Biogen Idec (NASDAQ BIIB) announced positive data from the Phase 3 DEFINE clinical” View full resource at drugs.com
Most Recently Shared on October 21, 2011 at 6:05 pm By:
Drugs and Devices OW OW Health
Oral BG-12 (Dimethyl Fumarate) Significantly Reduced Multiple Sclerosis (MS) Relapses and Disability Progr... http://t.co/jn7sS4EA #drug
Active Biotech gets boost from late-stage oral MS program - FierceBiotech
fiercebiotech.com — “Active Biotech's ($ACTI) shares jumped after its partner Teva Pharmaceutical ($TEVA) touted results of a late-stage trial for an oral multiple sclerosis drug under development with Active. While Read more...” View full resource at fiercebiotech.com
Most Recently Shared on March 16, 2012 at 1:28 pm By:
Active Biotech gets boost from late-stage oral MS program http://t.co/2VmTT4G7 $ACTI $TEVA #biotech
Oral Drug For MS Significantly Reduces Disease Activity And Slows Disability
medicalnewstoday.com — “The drug laquinimod reduced the number of relapses for people with multiple sclerosis (MS), in a large, long-term Phase III clinical study that will be presented as late-breaking research at the 6” View full resource at medicalnewstoday.com
Most Recently Shared on April 12, 2011 at 1:11 pm By:
Oral Drug For MS Significantly Reduces Disease Activity And Slows Disability: The drug laquinimod reduced the nu... http://bit.ly/ekuFKc
Oral Drug For MS Significantly Reduces Disease Activity And Slows Disability
medicalnewstoday.com — “The drug laquinimod reduced the number of relapses for people with multiple sclerosis (MS), in a large, long-term Phase III clinical study that will be presented as late-breaking research at the 6” View full resource at medicalnewstoday.com
Most Recently Shared on April 12, 2011 at 7:05 am By:
MNT Neurology News Neurology and Health News
Oral Drug For MS Significantly Reduces Disease Activity And Slows Disability http://mnt.to/3TtH #neurology
FDA Approves 1st Oral Drug for MS Relapses - Drugs.com MedNews
drugs.com — “The U.S. Food and Drug Administration on Wednesday approved the first oral drug to treat relapses of multiple sclerosis, the nervous system disorder that has tr” View full resource at drugs.com
Most Recently Shared on September 22, 2010 at 5:12 pm By:
Drugs and Devices OW OW Health
FDA Approves 1st Oral Drug for MS Relapses: WEDNESDAY, Sept. 22 -- The U.S. Food and Drug Administration on W... http://bit.ly/9DDXUt #drug
Medical News:Drug Delays Disability in MS - in Clinical Context, Multiple Sclerosis from MedPage Today
medpagetoday.com — “Medical News:Drug Delays Disability in MS - in Clinical Context, Multiple Sclerosis from MedPage Today” View full resource at medpagetoday.com
Most Recently Shared on March 15, 2012 at 11:30 am By:
Drug Delays Disability in MS (CME/CE): (MedPage Today) -- The investigational oral multiple sclerosis drug laqui... http://t.co/z1HVf26b
The Top 3 resources shared on this topic. More resources.
Key stats and trends about this topic
Related WisdomCards
Related Health Centers
Featuring the top 3 experts for this topic
-
Scott Strumello
-
Carmen Drahl
Science reporter and blogger at Chemical & Engineering News. PhD chemist. Follow me and get the molecular goings-on in pharma, biotech, and academia.
-
Jim Edwards
Writer for CBS Interactive's BNET, Adweek and Brandweek.
Advertisement
